What medications, besides antidepressants, are used to treat post‑traumatic stress disorder (PTSD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications for PTSD Beyond Antidepressants

For PTSD-associated nightmares specifically, prazosin is the most strongly recommended non-antidepressant medication, while for broader PTSD symptoms, atypical antipsychotics (risperidone, aripiprazole, olanzapine) represent the best-supported non-antidepressant pharmacologic options.

Primary Non-Antidepressant Options

Prazosin (Alpha-1 Adrenergic Antagonist)

Prazosin is recommended (Level A evidence) specifically for PTSD-associated nightmares 1. This is the strongest non-antidepressant recommendation in the guidelines.

  • Dosing approach: Start at 1 mg at bedtime, increase by 1-2 mg every few days until effective
  • Typical effective dose: Average ~3 mg, though range is 1-13 mg/day (higher doses often needed for combat veterans)
  • Evidence: Three Level 1 placebo-controlled trials showed statistically significant reduction in trauma-related nightmares (CAPS nightmare scores improved from 4.8-6.9 to 3.2-3.6)
  • Key monitoring: Watch for orthostatic hypotension
  • Mechanism: Reduces elevated CNS noradrenergic activity that disrupts REM sleep and contributes to nightmares and hyperarousal 1

Atypical Antipsychotics

These represent the next tier of non-antidepressant options, particularly as augmentation therapy 2:

Risperidone has the strongest evidence among antipsychotics 3:

  • Demonstrated moderate-to-high efficacy in treating PTSD-related nightmares
  • Dosing: 0.5-3 mg/day (average 2.3 mg)
  • One 12-week trial showed significant decrease in nightmare frequency (38% to 19% of nights)
  • Works via alpha-1 and alpha-2 noradrenergic antagonism 2

Olanzapine and Aripiprazole may also be used 2:

  • Olanzapine: 10-20 mg/day, increases slow-wave sleep and reduces REM
  • Limited but positive case series data
  • Consider as augmentation when SSRIs/SNRIs provide insufficient response

Secondary Non-Antidepressant Options

Clonidine (Alpha-2 Agonist)

  • May be considered (Level C) for PTSD-associated nightmares 1
  • Dosing: 0.2-0.6 mg in divided doses
  • Shares therapeutic rationale with prazosin but less rigorously studied
  • Monitor for postural hypotension
  • Has been used for over 20 years in severely traumatized refugees, though lacks randomized controlled trials 1

Additional Agents with Lower-Grade Evidence (Level C)

The following may be considered but have sparse data 1:

For nightmares/sleep disturbances:

  • Trazodone: 25-600 mg (mean 212 mg); 72% reported decreased nightmares in one study, but 60% experienced side effects (sedation, dizziness, priapism)
  • Triazolam and nitrazepam: Benzodiazepine receptor agonists for nightmare disorder specifically 2

Other options:

  • Topiramate: Anticonvulsant with some supporting data
  • Gabapentin: May help with hyperarousal symptoms
  • Cyproheptadine: Antihistamine with antiserotonergic properties
  • Phenelzine: MAOI (requires dietary restrictions)
  • Nabilone: Synthetic cannabinoid (limited evidence)

Important Contraindications

The following are NOT recommended 2:

  • Clonazepam: Specifically not recommended for nightmare disorder
  • Venlafaxine: Not recommended for nightmare disorder (though it IS recommended as first-line for general PTSD as an SNRI)
  • Benzodiazepines generally: The 2024 VA/DoD guideline recommends AGAINST benzodiazepines, cannabis, or cannabis-derived products for PTSD 4

Clinical Algorithm for Non-Antidepressant Selection

Step 1: If nightmares are the predominant symptom → Start prazosin

Step 2: If inadequate response to SSRIs/SNRIs for general PTSD symptoms → Add risperidone (strongest augmentation evidence)

Step 3: If nightmares persist despite prazosin → Consider adding trazodone at bedtime (though monitor for side effects)

Step 4: For treatment-refractory cases → Consider olanzapine or aripiprazole as augmentation, or trial topiramate or gabapentin

Step 5: If insomnia without nightmares → Clonidine may be considered, though avoid benzodiazepines

Critical Caveats

  • Most studies evaluated these medications as augmentation to ongoing psychotherapy and other psychotropics, not as monotherapy 1
  • Psychotherapy (particularly trauma-focused CBT) remains first-line treatment and should not be replaced by pharmacotherapy alone 4
  • Evidence for non-antidepressant medications is generally weaker than for SSRIs/SNRIs (only sertraline and paroxetine are FDA-approved for PTSD) 4, 5
  • Many promising agents have failed in late-stage trials due to high placebo response rates and patient heterogeneity 6
  • Avoid the temptation to use benzodiazepines despite their anxiolytic properties—they may actually increase PTSD risk and are explicitly not recommended 4, 5

References

Guideline

best practice guide for the treatment of nightmare disorder in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010

Guideline

position paper for the treatment of nightmare disorder in adults: an american academy of sleep medicine position paper.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018

Research

Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Progress in neuro-psychopharmacology & biological psychiatry, 2009

Research

PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER.

Georgian medical news, 2023

Research

Investigational drugs in PTSD.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.